308 related articles for article (PubMed ID: 34093569)
21. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
Almerie MQ; Kerrigan DD
Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
[TBL] [Abstract][Full Text] [Related]
22. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
23. Heme oxygenase-1 (HO-1) cytoprotective pathway: A potential treatment strategy against coronavirus disease 2019 (COVID-19)-induced cytokine storm syndrome.
Rossi M; Piagnerelli M; Van Meerhaeghe A; Zouaoui Boudjeltia K
Med Hypotheses; 2020 Nov; 144():110242. PubMed ID: 33254548
[TBL] [Abstract][Full Text] [Related]
24. Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19.
Ricciotti E; Laudanski K; FitzGerald GA
Adv Biol Regul; 2021 Aug; 81():100818. PubMed ID: 34303107
[TBL] [Abstract][Full Text] [Related]
25. The cytokine storm and COVID-19.
Hu B; Huang S; Yin L
J Med Virol; 2021 Jan; 93(1):250-256. PubMed ID: 32592501
[TBL] [Abstract][Full Text] [Related]
26. COVID-19 and Vitamin D: A lesson from the skin.
Slominski RM; Stefan J; Athar M; Holick MF; Jetten AM; Raman C; Slominski AT
Exp Dermatol; 2020 Sep; 29(9):885-890. PubMed ID: 32779213
[TBL] [Abstract][Full Text] [Related]
27. Berberine reduces circulating inflammatory mediators in patients with severe COVID-19.
Zhang BY; Chen M; Chen XC; Cao K; You Y; Qian YJ; Yu WK
Br J Surg; 2021 Jan; 108(1):e9-e11. PubMed ID: 33640910
[No Abstract] [Full Text] [Related]
28. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
29. Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling.
Gajjela BK; Zhou MM
Drug Discov Today; 2022 Feb; 27(2):390-400. PubMed ID: 34743903
[TBL] [Abstract][Full Text] [Related]
30. Potential therapeutic effects of Resveratrol against SARS-CoV-2.
Ramdani LH; Bachari K
Acta Virol; 2020; 64(3):276-280. PubMed ID: 32985211
[TBL] [Abstract][Full Text] [Related]
31. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
32.
Mardi A; Meidaninikjeh S; Nikfarjam S; Majidi Zolbanin N; Jafari R
Viral Immunol; 2021 Dec; 34(10):679-688. PubMed ID: 34882013
[TBL] [Abstract][Full Text] [Related]
33. Quinacrine as a potential treatment for COVID-19 virus infection.
Pineda B; Pérez de la Cruz V; Hernández Pando R; Sotelo J
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):556-566. PubMed ID: 33506949
[TBL] [Abstract][Full Text] [Related]
34. Management of SARS-CoV-2 pneumonia.
Sagnelli C; Celia B; Monari C; Cirillo S; De Angelis G; Bianco A; Coppola N
J Med Virol; 2021 Mar; 93(3):1276-1287. PubMed ID: 32856728
[TBL] [Abstract][Full Text] [Related]
35. Nebulized Lidocaine in COVID-19, An Hypothesis.
Ali ZA; El-Mallakh RS
Med Hypotheses; 2020 Nov; 144():109947. PubMed ID: 32505070
[TBL] [Abstract][Full Text] [Related]
36. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
[TBL] [Abstract][Full Text] [Related]
37. Target-Specific Drug Discovery of Natural Products against SARS-CoV-2 Life Cycle and Cytokine Storm in COVID-19.
Lee M; Park J; Cho IH
Am J Chin Med; 2022; 50(4):927-959. PubMed ID: 35729089
[TBL] [Abstract][Full Text] [Related]
38.
Khan FI; Hassan F; Lai D
Front Immunol; 2021; 12():794780. PubMed ID: 35095870
[TBL] [Abstract][Full Text] [Related]
39. A comprehensive review on sarilumab in COVID-19.
Khiali S; Rezagholizadeh A; Entezari-Maleki T
Expert Opin Biol Ther; 2021 May; 21(5):615-626. PubMed ID: 33161757
[No Abstract] [Full Text] [Related]
40. Proposed use of thalidomide for the cytokine storm of COVID-19.
Goihman-Yahr M
Clin Dermatol; 2020; 38(4):508. PubMed ID: 32972614
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
